(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Figure out How to Augment Eco-friendliness in Your Volvo XC40 - 2Luigi Mangione‘s lawyers say Bondi’s death penalty decision was tainted by conflict of interest
- 3How to watch ‘The Traitors’ U.K. Season 4 premiere today from the U.S.
- 4Exploring the Market: Unsold Rams May Be Less expensive Than You Naturally suspect
- 5Finding China: Four Urban areas for a Remarkable Excursion
- Computerized Moderation: Tracking down Equilibrium in the Advanced Age
- Nutrient Rich Organic products: Lift Your Wellbeing
- Looking for under-the-radar adventures? Try Norway's Vesterålen
- A definitive Manual for Internet Mastering and Expertise Improvement
- Mom finds out she has cancer after noticing something was off while breastfeeding
- The Minimized Passage Horse: Reconsidering a Symbol for the Cutting edge Period
- Working out at the airport? Some fliers can already smell the sweat.
- Foods with healthy-sounding buzzwords could be hiding added sugar in plain sight
- Moving Wedding Objections for Paramount Functions
